Another study indicated p21 (RAC1) activated kinase 6 (PAK6) as a critical regulator of the DDR and chemoresistance in gastric cancer, particularly in relation to oxaliplatin, another commonly used bifunctional alkylating agent. Here, PAK6 is linked to gastric cancer.